Загрузка...

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...

Полное описание

Сохранить в:
Библиографические подробности
Главный автор: Petrylak, Daniel P
Формат: Artigo
Язык:Inglês
Опубликовано: MedReviews, LLC 2003
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1502327/
https://ncbi.nlm.nih.gov/pubmed/16986041
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!